Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? (Q37968946)

26 August 2017

title

Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? (English)

1 reference

26 August 2017

0 references

0 references

0 references

Bernhard J Connemann

2

0 references

Hayrettin Tumani

series ordinal

4

object named as

Hayrettin Tumani

1 reference

26 August 2017

Nenad Vasic

1

1 reference

26 August 2017

Robert C Wolf

series ordinal

3

1 reference

26 August 2017

Johannes Brettschneider

series ordinal

5

1 reference

26 August 2017

publication date

16 December 2011

1 reference

European Archives of Psychiatry and Clinical Neuroscience

26 August 2017

published in

1 reference

26 August 2017

volume

262

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

375-391

1 reference

Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Tripartite synapses: glia, the unacknowledged partner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Impairment of the blood-brain barrier as an aetiological factor in paranoid psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Brain derived neurotropic factor in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Synaptotagmin: a Ca(2+) sensor that triggers exocytosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

SNAP-25 in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Role of cannabis and endocannabinoids in the genesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

CSF metabolic and proteomic profiles in patients prodromal for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

[Proteomics: biomarker research in psychiatry]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

GSK3 signalling in neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The 100-year epidemiology of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Glial cells in the enteric nervous system contain glial fibrillary acidic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Role of VGF-derived peptides in the control of food intake, body weight and reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Abnormal cerebrospinal fluid protein indices in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The role of glycogen synthase kinase-3beta in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Low GSK-3 activity in frontal cortex of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid diagnostics in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cytokines and the brain: implications for clinical psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Antibodies to infectious agents in individuals with recent onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Does BDNF have pre- or postsynaptic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Is the word 'biomarker' being properly used by proteomics research in neuroscience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Clinical proteomics: A need to define the field and to begin to set adequate standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

SNAP-25 gene polymorphisms and weight gain in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-serine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

GSK-3 parameters in lymphocytes of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Evidence of disturbed CSF circulation and brain atrophy in cases of schizophrenic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased frequency of aberrant CSF circulation in schizophrenic patients compared to healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The role of proteomics in investigating psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

An ELISA for glial fibrillary acidic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Progressive structural brain changes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Dynamics of brain-derived proteins in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Neurobiology: signals that make waves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

A sensitive ELISA for glial fibrillary acidic protein: application in CSF of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

IgG synthesis within the central nervous system. Comparison of three formulas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid: identification of diagnostic markers for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The reduced neuropil hypothesis: a circuit based model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Neuropeptides in depression: role of VGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Elevated cerebrospinal fluid SNAP-25 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Immunoglobulins and Viral Antibodies in Psychiatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Permeability of the blood-brain barrier in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Changes in cortical thickness during the course of illness in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Elevated plasma levels of S-100b protein in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Endocannabinoid signaling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Are some cases of psychosis caused by microbial agents? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Apoptosis in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

The S100 protein family: history, function, and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Blood-cerebrospinal fluid barrier in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0280-9

14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

21 January 2018

1 reference

12 December 2020

Immunoglobulins, prealbumin, transferrin, albumin, and alpha2-macroglobulin in cerebrospinal fluid and serum in schizophrenic patients

1 reference

12 December 2020

Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia

1 reference

12 December 2020

SNPs and haplotypes in the S100B gene reveal association with schizophrenia

1 reference

12 December 2020

Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology

1 reference

12 December 2020

Increased serum S100B protein in schizophrenia: a study in medication-free patients

1 reference

12 December 2020

Cerebrospinal fluid analysis.

1 reference

12 December 2020

Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia

1 reference

12 December 2020

S100B in schizophrenia: an update

1 reference

12 December 2020

Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment

1 reference

12 December 2020

Viruses and schizophrenia: a focus on herpes simplex virus

1 reference

12 December 2020

Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients

1 reference

12 December 2020

CSF-studies in neuropsychiatric disorders.

1 reference

12 December 2020

Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia

1 reference

12 December 2020

Sex differences in total protein content of cerebrospinal fluid

1 reference

12 December 2020

Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes

1 reference

12 December 2020

S-100 protein, but not calmodulin, binds to the glial fibrillary acidic protein and inhibits its polymerization in a Ca(2+)-dependent manner.

1 reference

12 December 2020

Cerebrospinal fluid tau protein levels in schizophrenia

1 reference

12 December 2020

Immunoreactive nervous system of specific enolase (14-3-2 protein) in human serum and cerebrospinal fluid

1 reference

12 December 2020

CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin)

1 reference

12 December 2020

Elevated endogenous cannabinoids in schizophrenia

1 reference

12 December 2020

Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity

1 reference

12 December 2020

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

12 December 2020

GSK-3beta in cerebrospinal fluid of schizophrenia patients.

1 reference

12 December 2020

Investigation of serum BDNF levels in drug-naive patients with schizophrenia

1 reference

12 December 2020

Elevated interleukin-6 in schizophrenia

1 reference

12 December 2020

gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders

1 reference

12 December 2020

Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake.

1 reference

12 December 2020

The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders

1 reference

12 December 2020

Antibodies to Infectious Agents in Individuals at Ultra-High Risk for Psychosis

1 reference

12 December 2020

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

1 reference

12 December 2020

On the τ-protein in cerebrospinal fluid

1 reference

12 December 2020

Levels in stroke patients of CSF astroprotein, an astrocyte-specific cerebroprotein

1 reference

12 December 2020

Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia

1 reference

12 December 2020

Omega-3 fatty acids and neuropsychiatric disorders

1 reference

12 December 2020

Biomarker discovery in psychiatric disorders

1 reference

12 December 2020

Neuron-specific Enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia

1 reference

12 December 2020

Selected infectious agents and risk of schizophrenia among U.S. military personnel

1 reference

12 December 2020

Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia

1 reference

12 December 2020

Identification of a molecular target for the calcium-modulated protein S100. Fructose-1,6-bisphosphate aldolase

1 reference

12 December 2020

Thyroxine transport to the brain: role of protein synthesis by the choroid plexus

1 reference

12 December 2020

CSF SNAP-25 in schizophrenia and bipolar illness. A pilot study

1 reference

12 December 2020

Cerebrospinal fluid in mental diseases (a study using paper electrophoresis).

1 reference

12 December 2020

Polyunsaturated fatty acid supplementation for schizophrenia

1 reference

12 December 2020

Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients

1 reference

12 December 2020

The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain

1 reference

12 December 2020

Abnormal cerebrospinal fluid total protein and gamma-blobulin levels in 256 patients admitted to a psychiatric unit

1 reference

12 December 2020

10.1007/S00406-011-0280-9

Identifiers

DOI

1 reference

26 August 2017

1 reference